摘要
目的探讨不同剂量布地奈德混悬液雾化治疗对毛细支气管炎患儿的治疗作用。方法 86例毛细支气管炎患儿被随机分为A组(30例)、B组(28例)和C组(28例),分别给予抗感染、吸氧、祛痰、镇静等综合治疗外,A组采用布地奈德混悬液雾化2 mg/d,B组1 mg/d,C组0.5 mg/d,疗程6个月。在治疗前及治疗后观察并记录三组症状改善时间及治疗过程中的不良反应;治疗后第7天进行疗效评价并随访记录2年时各组患儿哮喘发病率、喘息发生情况。结果三组间临床疗效总有效率比较,A组和B组明显高于C组(P<0.05);三组在咳嗽消失、发绀消失、气促缓解、肺部哮鸣音消失时间上比较,差异存在显著性(P<0.05);随访2年,三组在发作次数、喘息持续时间、首次喘息复发时间及哮喘发病率上比较,差异存在显著性(P<0.01),A组明显优于其余两组,B组次之。结论大剂量布地奈德混悬液雾化吸入治疗毛细支气管炎安全有效,并减少日后发生哮喘的危险性。
Objective To investigate the clinical effects of different dosing regimens of budesonide respules to treat capillary bronchiolitis. Methods 86 cases with capillary bronchiolitis were randomly divided into 3 groups: A group( 30 cases) , B group( 28 cases) and C group( 28 cases). A group received budesonide respules 2 mg/d, B group received budesonide respules 1 mg/d and C group received budesonide respules 0.5 mg/d. The time on improvement of symptoms,the occurrence of wheezing and asthma morbidity in 2 years were observed in these 3 groups. Results The total effective rate of A group and B group were higher than that of C group. The diference in improvement of symptoms show significant difference in three groups. A group obtained a better clinical curative effect on intervene asthma morbidity than other two groups. Conclusion It's effective, safe and quick to treat capillary bronchiolitis with high dosing regimens of budesonide respules, and it will decrease asthma morbidity.
出处
《中国医学创新》
CAS
2010年第20期53-55,共3页
Medical Innovation of China